Instrument Inactif

Communiqués Tonix Pharmaceuticals Holding Corp Nasdaq

Actions

US8902602015

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

10/08	Transcript : Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
10/08	Tonix Pharmaceuticals Holding Corp. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

10/08	Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights	AQ
05/08	Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
03/08	Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.	AQ
27/07	Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026	AQ
15/07	Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models	AQ
13/07	Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®	AQ
29/06	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)	AQ
11/06	Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026	AQ
08/06	Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives	AQ
28/05	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting	AQ
27/05	Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology	AQ
26/05	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting	AQ
18/05	TNX-1500 for Prevention of Kidney Transplant Rejection and Autoimmune Disorders: 2nd Richard Slayman Clinical Xenotransplantation Workshop Presentation	PU
15/05	TNX-4800 for the Prevention of Lyme disease in the U.S.: Global Lyme Alliance Presentation	PU
14/05	Tonix Pharmaceuticals : May 2026 Investor Deck	PU
14/05	Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026	AQ
12/05	Tonix Pharmaceuticals to Participate in Two Investor Conferences in May	AQ
11/05	Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights	AQ
06/05	Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients	AQ
06/05	Tonix Pharmaceuticals : TNX-4800 for the Prevention of Lyme disease in the U.S.	PU
29/04	Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University	AQ
23/04	Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026	AQ
15/04	Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development	AQ
07/04	Tonix Pharmaceuticals : April 2026 Investor Deck	PU
01/04	Tonix Pharmaceuticals : April 2026 Investor Deck	PU